Originally published by our sister publication Specialty Pharmacy Continuum
By Marcus A. Banks
The FDA has authorized imports of cisplatin from China, as this crucial medication remains in short supply in the United States due to a halt in cisplatin production by the Indian manufacturer Intas Pharmaceuticals following a 2022 FDA inspection that raised concerns about the company’s manufacturing process.
The agency may allow imports for carboplatin, another chemotherapy medication facing a